This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

Inclusion Criteria

• Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer
• Recurrent ovarian cancer or persistent disease following primary treatment
• At least one, but no more than four, prior chemotherapy regimens (all platinum-containing counted as one)
• At least 18 years of age

Exclusion Criteria

• Pregnant or lactating women
• History of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which patient has been disease-free for at least 2 years
• Known leptomeningeal metastases or carcinomatous meningitis
• Having received whole pelvis radiation therapy